Heart failure in dilated non-ischaemic cardiomyopathy
Сердечная недостаточность при дилатационной неишемической кардиомиопатии
2019-12-01
SCID: 54.1/wjm9qasx
Discuss with AI
Dilated non-ischaemic cardiomyopathyGenetic cardiomyopathyHeart failureImplantable cardioverter-defibrillatorLeft ventricular dysfunction
Figures from the paper
Abstract (AI)
Heart failure (HF) is the prevailing cause of morbidity and mortality in patients with dilated non-ischaemic cardiomyopathy (DCM) and DCM is one of several causes of HF, with several distinct epidemiological and clinical features which may have important implications for its management and prognosis. This article reviews cardiovascular monitoring of specific characteristics of HF in DCM. DCM is defined as ventricular dilatation and systolic dysfunction in the absence of abnormal loading conditions or significant coronary artery disease, the predominant phenotypes of being HFmrEF or HFrEF. DCM accounts for ∼40% of all cardiomyopathies but its true prevalence among patients with HFrEF is difficult to ascertain with certainty. Compared with patients with other HF aetiologies, individuals with DCM tend to be younger, more likely male and less likely to have associated comorbidities. A genetic aetiology of DCM is deemed responsible for ∼40% of cases. Confirmation of a specific genetic background is clinically relevant (e.g. Duchene or Backer muscular dystrophies, lamin A/C mutation), because those patients may be at a high risk of progressive left ventricular dysfunction or conduction system disease and sudden death, prompting early prophylaxis with an implantable cardioverter defibrillator. However, in most instances, HF in DCM has a multifactorial aetiology, with multiple factors needing to be systematically evaluated and/or monitored, since correction of reversible causes or (e.g. tachycardia-induced cardiomyopathy, alcohol intoxication, iron-overload, cancer therapies etc.) or targeting specific pathophysiological causes could lead to an improvement in clinical status. The treatment of DCM encompasses HF-related pharmacological and device therapies, and aetiology-specific treatments. At present, options for aetiology-related therapies are limited, and their effectiveness mostly requires confirmation from larger scale randomized trials. Whether outcomes of patients with HF in DCM differ from those with other HF aetiologies is unresolved. DCM is attributable for >40% of patients receiving mechanical circulatory support for advanced HF and it is the leading indication for heart transplantation. More aetiology-specific information is needed both in the evaluation and treatment of dilated cardiomyopathy.
Key Findings
1
Compared with patients having other heart-failure causes, patients with DCM are generally younger, more often male, and have fewer associated comorbidities.
2
DCM accounts for approximately 40% of cardiomyopathies, although its prevalence among patients with HFrEF remains uncertain.
3
Dilated non-ischaemic cardiomyopathy is defined by ventricular dilatation and systolic dysfunction without abnormal loading conditions or significant coronary artery disease, predominantly presenting as HFmrEF or HFrEF.
4
Genetic causes account for approximately 40% of DCM cases; identifying high-risk mutations can support early implantable cardioverter-defibrillator prophylaxis because of risks for progressive dysfunction, conduction disease, and sudden death.
5
Systematic evaluation for reversible or specific causes—including tachycardia, alcohol, iron overload, and cancer therapies—may improve clinical status, while most aetiology-specific treatments still require confirmation in larger randomized trials.
Research Object
Heart failure in patients with dilated non-ischaemic cardiomyopathy (DCM)
Research Subject
Cardiovascular monitoring, clinical characteristics, aetiologies, prognosis, and management of heart failure in DCM
Publication Details
Publication Date
2019-12-01
Journal
Publisher
ISSN
Cited by
33
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest